🆙#ESMO26 Proffered Paper I: #LCSM Mets 🔥PERSEE (GFPC 01-2020): Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%, Phase 3 Trial 🎙️ @decroisette 🔢2614O 🎯Pembro-Chemo Improved BCR-PFS vs Pembro Alone 🎯PFS HR 0.56, mPFS 16.1 vs 6.9m 🎯OS HR 0.77 not significant; mOS 50.2 vs 29.9mo 🎯Grade≥3 TRAEs 53.8% vs 19.3% ☑️NCT04547504 🔗 https://t.co/uGHKJfiJGo @OncoAlert @Larvol @myESMO @IASLC